Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

599 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical and regulatory landscape for cardiogenic shock: A report from the Cardiac Safety Research Consortium ThinkTank on cardiogenic shock.
Samsky M, Krucoff M, Althouse AD, Abraham WT, Adamson P, Aguel F, Bilazarian S, Dangas GD, Gilchrist IC, Henry TD, Hochman JS, Kapur NK, Laschinger J, Masters RG, Michelson E, Morrow DA, Morrow V, Ohman EM, Pina I, Proudfoot AG, Rogers J, Sapirstein J, Senatore F, Stockbridge N, Thiele H, Truesdell AG, Waksman R, Rao S. Samsky M, et al. Among authors: abraham wt. Am Heart J. 2020 Jan;219:1-8. doi: 10.1016/j.ahj.2019.10.006. Epub 2019 Nov 7. Am Heart J. 2020. PMID: 31707323 Free PMC article. Review. No abstract available.
Cardiac Resynchronization Therapy for Advanced Heart Failure.
Adamson PB, Abraham WT. Adamson PB, et al. Among authors: abraham wt. Curr Treat Options Cardiovasc Med. 2003 Aug;5(4):301-309. doi: 10.1007/s11936-003-0029-5. Curr Treat Options Cardiovasc Med. 2003. PMID: 12834567
Clinical predictors and timing of New York Heart Association class improvement with cardiac resynchronization therapy in patients with advanced chronic heart failure: results from the Multicenter InSync Randomized Clinical Evaluation (MIRACLE) and Multicenter InSync ICD Randomized Clinical Evaluation (MIRACLE-ICD) trials.
Pires LA, Abraham WT, Young JB, Johnson KM; MIRACLE and MIRACLE-ICD Investigators. Pires LA, et al. Among authors: abraham wt. Am Heart J. 2006 Apr;151(4):837-43. doi: 10.1016/j.ahj.2005.06.024. Am Heart J. 2006. PMID: 16569543
Low-dose oral enoximone enhances the ability to wean patients with ultra-advanced heart failure from intravenous inotropic support: results of the oral enoximone in intravenous inotrope-dependent subjects trial.
Feldman AM, Oren RM, Abraham WT, Boehmer JP, Carson PE, Eichhorn E, Gilbert EM, Kao A, Leier CV, Lowes BD, Mathier MA, McGrew FA, Metra M, Zisman LS, Shakar SF, Krueger SK, Robertson AD, White BG, Gerber MJ, Wold GE, Bristow MR; EMOTE Study Group. Feldman AM, et al. Among authors: abraham wt. Am Heart J. 2007 Nov;154(5):861-9. doi: 10.1016/j.ahj.2007.06.044. Epub 2007 Sep 6. Am Heart J. 2007. PMID: 17967591 Clinical Trial.
Randomized controlled trial of an implantable continuous hemodynamic monitor in patients with advanced heart failure: the COMPASS-HF study.
Bourge RC, Abraham WT, Adamson PB, Aaron MF, Aranda JM Jr, Magalski A, Zile MR, Smith AL, Smart FW, O'Shaughnessy MA, Jessup ML, Sparks B, Naftel DL, Stevenson LW; COMPASS-HF Study Group. Bourge RC, et al. Among authors: abraham wt. J Am Coll Cardiol. 2008 Mar 18;51(11):1073-9. doi: 10.1016/j.jacc.2007.10.061. J Am Coll Cardiol. 2008. PMID: 18342224 Free article. Clinical Trial.
A randomized controlled trial to evaluate the safety and efficacy of cardiac contractility modulation in patients with systolic heart failure: rationale, design, and baseline patient characteristics.
Abraham WT, Burkhoff D, Nademanee K, Carson P, Bourge R, Ellenbogen KA, Parides M, Kadish A; FIX-HF-5 Investigators and Coordinators. Abraham WT, et al. Am Heart J. 2008 Oct;156(4):641-648.e1. doi: 10.1016/j.ahj.2008.05.019. Am Heart J. 2008. PMID: 18926146 Clinical Trial.
599 results